Weight Gain Mitigation with Topiramate in Mood Disorders

Woods, Tonja; Eichner, Samantha; Franks, Andrea S.

doi:10.1345/aph.1d219

Cited by 11 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A few preliminary studies have reported decreased appetite or weight loss in patients treated with TPM for BD (Gordon and Price 1995; Nemeroff 2003; Woods et al 2004). …”

Section: Rationale For the Use Of Topiramate In Affective Disordersmentioning

confidence: 99%

Psychopharmacology of topiramate: from epilepsy to bipolar disorder

Mula¹,

Cavanna²,

Monaco³

2006

Neuropsychiatric Disease and Treatment

View full text Add to dashboard Cite

Topiramate (TPM) is one of the novel antiepileptic drugs and exhibits a wide range of mechanisms of action. Effi cacy of TPM has been demonstrated in partial-onset seizures and primary generalized seizures in adults and children, as both monotherapy and adjunctive therapy. More recently, TPM has been proposed as an add-on treatment for patients with lithiumresistant bipolar disorder, especially those displaying rapid-cycling and mixed states. This paper reviews the multiple mechanisms of action and the tolerability profi le of TPM in the light of its therapeutic potential in affective disorders. Studies of TPM in bipolar disorder are evaluated, and the effi cacy and tolerability issues as a mood stabilizing agent are discussed.

show abstract

“…A few preliminary studies have reported decreased appetite or weight loss in patients treated with TPM for BD (Gordon and Price 1995; Nemeroff 2003; Woods et al 2004). …”

Section: Rationale For the Use Of Topiramate In Affective Disordersmentioning

confidence: 99%

Psychopharmacology of topiramate: from epilepsy to bipolar disorder

Mula¹,

Cavanna²,

Monaco³

2006

Neuropsychiatric Disease and Treatment

View full text Add to dashboard Cite

show abstract

“…Resveratrol (3,5,4Ј-trihydroxystilbene) is a polyphenolic compound found in grape skins that has been shown to increase lifespan in various organisms, promoting effects similar to those induced by caloric restriction (1)(2)(3). In rodents, a 20 -40% reduction in calorie intake extends lifespan by ϳ50% (4).…”

mentioning

confidence: 99%

Resveratrol Potentiates Glucose-stimulated Insulin Secretion in INS-1E β-Cells and Human Islets through a SIRT1-dependent Mechanism

Vetterli¹,

Brun²,

Giovannoni

et al. 2011

Journal of Biological Chemistry

152

126

View full text Add to dashboard Cite

“…Studies in rodents suggested an effect in inducing weight loss [40]. It was also observed that topiramate may mitigate weight gain observed with anti-depressant use [41]. Based on these observations, three-randomized controlled studies of weight loss have been published [42][43][44].…”

Section: Topiramate (Topamax)mentioning

confidence: 99%

Pharmacologic Treatment of Obesity

Sidhaye¹

2006

Health and Treatment Strategies in Obesity

View full text Add to dashboard Cite

Obesity is strongly associated with conditions such as hypertension, diabetes mellitus and osteoarthritis that have known adverse health outcomes. The rising prevalence of obesity threatens to overburden our health care system. As a result, the need for safe and effective treatment options is urgent. Unfortunately, pharmacologic treatment options have been disappointing either because of poor side effect profiles or limited long-term efficacy. Our goal is to review currently available pharmacologic treatments and the data supporting their use so that practicing physicians may better incorporate them into a comprehensive, long-term treatment strategy for their patients. We focus on orlistat and sibutramine as these are the two medicines approved by the FDA for long-term treatment of obesity. In addition, we review briefly agents approved for short-term use as well as agents such as zonisamide and topiramate which have shown some promise as weight loss agents in specific clinical circumstances. Finally, we highlight one medicine currently in phase III clinical trials, an endocannabinoid receptor antagonist. Given the overwhelming research focus on this disease, it is likely that the coming years will bring more treatment options, raising the chance that our patients will have meaningful and sustained weight loss.

show abstract

Weight Gain Mitigation with Topiramate in Mood Disorders

Abstract: Current evidence suggests an association between topiramate and weight loss. Based on the limited data, controlled studies need to be conducted to define the role of topiramate in patients with mood disorders who would also benefit from weight reduction.

Cited by 11 publications

References 22 publications

Psychopharmacology of topiramate: from epilepsy to bipolar disorder

Psychopharmacology of topiramate: from epilepsy to bipolar disorder

Resveratrol Potentiates Glucose-stimulated Insulin Secretion in INS-1E β-Cells and Human Islets through a SIRT1-dependent Mechanism

Pharmacologic Treatment of Obesity

Contact Info

Product

Resources

About